Hjem › Mantelcellelymfom › Minnesota
Kliniske studier for Mantelcellelymfom i Minnesota
14 studier for Mantelcellelymfom søker deltakere på steder i Minnesota.
Byer i Minnesota
Offisiell studietekst (engelsk)
Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma
- Sanford Joe Lueken Cancer Center, Bemidji
- Essentia Health Saint Joseph's Medical Center, Brainerd
- Mercy Hospital, Coon Rapids
- og 13 flere
RekruttererFase 3
Alder 60 og eldre · Alle kjønn · Oppdatert 2. okt. 2026 · NCT05976763A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
- Research Site, Rochester
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 30. sep. 2026 · NCT06542250A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
- Mayo Clinic Rochester, Rochester
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 28. sep. 2026 · NCT06742996A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- Mayo Clinic Rochester, Rochester
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 28. sep. 2026 · NCT05006716A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
- Mayo Clinic - Rochester, Rochester
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 22. sep. 2026 · NCT07101328Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- Mayo Clinic, Clinical Trials Referral Office, Rochester
RekruttererFase 1/2
Alder 13 til 90 · Alle kjønn · Oppdatert 6. aug. 2026 · NCT06533579DALY II USA/ MB-CART2019.1 for DLBCL
- Mayo Clinic, Rochester
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 13. jul. 2026 · NCT04792489Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
- Masonic Cancer Center at University of Minnesota, Minneapolis
RekruttererFase 2
Opp til 60 år · Alle kjønn · Oppdatert 25. jun. 2026 · NCT03314974Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors, the HALT Study
- Mayo Clinic in Rochester, Rochester
RekruttererObservasjonsstudie
Alle aldre · Alle kjønn · Oppdatert 27. feb. 2026 · NCT06151730BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma
- Mayo Clinic, Rochester
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 20. feb. 2026 · NCT06854003BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL
- University of Minnesota, Minneapolis
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 20. nov. 2025 · NCT05370430Auto Stem Cell Transplant for Lymphoma Patients
- Masonic Cancer Center, University of Minnesota, Minneapolis
RekruttererFase 2
Opp til 75 år · Alle kjønn · Oppdatert 4. nov. 2025 · NCT03125642SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Duluth
RekruttererObservasjonsstudie
Alle aldre · Alle kjønn · Oppdatert 28. okt. 2025 · NCT03452774Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
- Mayo Clinic in Rochester, Rochester
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 18. nov. 2024 · NCT05910801Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.